Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ARR-002

Other · developed by ArriVent BioPharma

Phase 1 Most advanced trial

AVBP Developer

1 Registered trials

What is ARR-002?

ARR-002 is an investigational agent studied in ovarian cancer, endometrial cancer, and platinum-resistant ovarian cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Oncology
Developer: ArriVent BioPharma, Inc. (AVBP)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07755436	Phase 1	Ovarian Cancer	Recruiting	AVBP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Endometrial CancerMetastatic Endometrial CancerMetastatic Ovarian CancerOvarian CancerPlatinum-resistant Ovarian Cancer (PROC)

More from ArriVent BioPharma

ARR-217 Phase 1 EGFR-TKI inhibitor based on investigator's choice Phase 3 Firmonertinib Phase 3

Sources

ClinicalTrials.gov NCT07755436

Updated Oct 11, 2026. Something wrong or missing? Report it on the AVBP page.

Follow AVBP, the company behind ARR-002

See AVBP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AVBP catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z